Japan continues to be a significant contributor to the Asia-Pacific (APAC) diabetes care devices market with almost 25% share in the region in 2022. Japan diabetes care market is set to grow at a compound annual growth rate (CAGR) of approximately 4% through 2030, driven by growth in type 2 diabetes among the aging population and lifestyle changes, says GlobalData, a leading data, and analytics company.

Insulin pens continue to be at the heart of medical device innovation in diabetes management due to advances in technology, ease of usage, patient satisfaction, and cost-effectiveness.

Ayshi Ganguly, Medical Devices Analyst at GlobalData, comments: “Novo Nordisk AS is currently the leading player in the diabetes device market, followed by Eli Lilly and Sanofi. Novo Nordisk AS has established its market position by continuously investing in the research and development and by working with other organizations to introduce advanced technologies into their insulin pens that make insulin administration as easy and convenient as possible.”

Biocorp and Novo Nordisk have recently stepped up their collaboration to commercialize Mallya smart sensors to the Japanese market in the first quarter of 2023. Mallya, which connects directly to Novo Nordisk’s existing insulin pens, will automatically collect, and record daily insulin injection data via a mobile application to track real-time therapy monitoring. Novo Nordisk claims to have launched Japan’s first smart insulin pen earlier this year.

Ganguly concludes: “Japan is one of the high-potential markets for the development of diabetes care devices. Further collaborations and innovations will enable domestic and foreign companies to expand their networks and increase market share in the country.”